Masimo (NASDAQ:MASI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Masimo (NASDAQ:MASI) from a hold rating to a buy rating in a research note released on Sunday.

Several other research analysts have also recently commented on the stock. Piper Sandler raised their target price on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. BTIG Research restated a “buy” rating and issued a $198.00 price target on shares of Masimo in a research report on Thursday, September 11th. Finally, Zacks Research raised shares of Masimo from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Masimo presently has an average rating of “Buy” and a consensus price target of $194.60.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $147.55 on Friday. The stock’s fifty day simple moving average is $147.88 and its 200 day simple moving average is $156.42. The stock has a market capitalization of $8.02 billion, a price-to-earnings ratio of -17.32 and a beta of 1.23. The company has a quick ratio of 1.61, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. Masimo has a 52-week low of $131.60 and a 52-week high of $194.88.

Masimo (NASDAQ:MASI) last announced its earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 EPS for the quarter, beating the consensus estimate of $1.22 by $0.11. The business had revenue of $370.90 million during the quarter, compared to the consensus estimate of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.Masimo’s revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.86 earnings per share. As a group, sell-side analysts forecast that Masimo will post 4.1 earnings per share for the current fiscal year.

Insider Transactions at Masimo

In related news, Director William R. Jellison bought 3,000 shares of the business’s stock in a transaction on Monday, August 11th. The stock was bought at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the transaction, the director directly owned 4,790 shares in the company, valued at $699,244.20. This represents a 167.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 16.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Masimo

A number of hedge funds have recently modified their holdings of MASI. Twin Tree Management LP acquired a new stake in Masimo during the first quarter valued at $29,000. MAI Capital Management increased its position in Masimo by 176.7% in the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 129 shares during the last quarter. Farther Finance Advisors LLC raised its stake in shares of Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 116 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Masimo during the 2nd quarter valued at about $37,000. Finally, Anderson Financial Strategies LLC acquired a new stake in shares of Masimo during the 1st quarter valued at about $49,000. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.